A Phase 3 interventional study of Meloxicam suppository and Meloxicam tablet in Spondylitis, Ankylosing, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
This study's enrollment of 192 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Browse Spondylitis, Ankylosing studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Meloxicam suppository
Drug: Meloxicam tablet
Drug: Indomethacin
Overall pain during the previous 48 hours assessed on a Visual Analogue Scale (VAS)
Time frame: 6 weeks
Functional Index of ankylosing spondylitis of Dougados
Time frame: 6 weeks
Overall assessment of disease activity by the patient on VAS
Time frame: 6 weeks
Overall assessment of disease activity by the investigator on a VAS
Time frame: 6 weeks
Global efficacy assessed by the patient (verbal rating scale)
Time frame: 6 weeks
Global efficacy assessed by the investigator (verbal rating scale)
Time frame: 6 weeks
Duration of morning stiffness
Time frame: 6 weeks
Evaluation of spinal pain by the investigator (verbal rating scale)
Time frame: 6 weeks
Assessment of Schober test
Time frame: 6 weeks
Assessment of Chest expansion
Time frame: 6 weeks
Assessment of Fingers - to - floor test
Time frame: 6 weeks
Assessment of Night pain (verbal rating scale)
Time frame: 6 weeks
Total number of study withdrawals
Time frame: 6 weeks
Number of study withdrawals due to lack of efficacy
Time frame: 6 weeks
Assessment of Paracetamol consumption
Time frame: 6 weeks
Assessment of Patient status with regard to disease condition
Time frame: 6 weeks
No study locations are listed for this record.
Ran from Jul 2001 to primary completion in May 2002, 10 months.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam